Skip to main content
. 2011 Mar 1;11(5):464–473. doi: 10.4161/cbt.11.5.14410

Figure 2.

Figure 2

Curcumin reduces clonogenicity of brain tumor cell lines DAOY (A), D283Med (B), U87 (C) and HSR-GBM1 (D) in a dose-dependent fashion. Equal number of cells were seeded and treated with the indicated nanocurcumin concentrations or void NVA622 nanoparticles (vehicle). Curcumin reduces the CD133-positive stem-like fraction in glioblastoma cell lines JHH-GBM14 (E) and HSR-GBM1, as well as D283Med medulloblastoma cell line (F). JHH-GBM14 (E) and HSR-GBM1 (F) cells were treated with void NVA622 nanoparticle (vehicle), 5, 10 or 20 µM nanocurcumin for 2 days and collected for flow cytometry analysis with CD133 antibodies. DAOY and D283Med (F) cells were treated with the same doses for only 1 day. *p < 0.05, **p < 0.01, ****p < 0.0001 compared to vehicle control.